Adrian Dasilva-Deabreu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adrian Dasilva-Deabreu has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Hector O. Ventura
Ochsner Medical Center, New Orleans, LA
11 shared publications Stacy A. Mandras
11 shared publicationsClement Eiswirth
10 shared publications- Carl J. Lavie
John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA
9 shared publications - Juan Francisco Loro-Ferrer
Departamento de Ciencias Clínicas, Universidad de las Palmas de Gran Canaria, 35016 Las Palmas, Spain
7 shared publications Carl J. Lavie
6 shared publications
Latest Publications
- 13 February 2026
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 28 (1) , 21
Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions
Purpose of Review This review examines the mechanistic pathways linking obesity and cardiovascular disease, with particular emphasis on recent advancements in pharmacologic therapies. It evaluates the cardiovascular effects of novel anti-obesity medications and their integration into current treatment paradigms. Additionally, these pharmacologic strategies are contextualized alongside lifestyle interventions and metabolic bariatric surgery. Recent Findings Incretin agonist therapies, including both glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have shown substantial efficacy in weight reduction and cardiometabolic improvement. Clinical trials have demonstrated that these agents not only reduce body weight by 10–20% but also significantly lower the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and stroke. These benefits have been observed in both patients with and without diabetes mellitus, and the cardiovascular protection extends beyond glycemic control. Tirzepatide, in particular, has shown superior efficacy compared to GLP-1 monotherapy in weight loss. Summary Pharmacologic therapy has become a central pillar in the management of obesity-related cardiovascular risk. The emergence of agents with proven efficacy in both weight reduction and cardiovascular outcome improvement marks a paradigm shift in treatment. These findings support early and sustained use of pharmacotherapy in high-risk individuals, highlighting a need for integrated, personalized care strategies in obesity management.
- 13 February 2026
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 28 (1) , 21
Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions
Purpose of Review This review examines the mechanistic pathways linking obesity and cardiovascular disease, with particular emphasis on recent advancements in pharmacologic therapies. It evaluates the cardiovascular effects of novel anti-obesity medications and their integration into current treatment paradigms. Additionally, these pharmacologic strategies are contextualized alongside lifestyle interventions and metabolic bariatric surgery. Recent Findings Incretin agonist therapies, including both glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have shown substantial efficacy in weight reduction and cardiometabolic improvement. Clinical trials have demonstrated that these agents not only reduce body weight by 10–20% but also significantly lower the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and stroke. These benefits have been observed in both patients with and without diabetes mellitus, and the cardiovascular protection extends beyond glycemic control. Tirzepatide, in particular, has shown superior efficacy compared to GLP-1 monotherapy in weight loss. Summary Pharmacologic therapy has become a central pillar in the management of obesity-related cardiovascular risk. The emergence of agents with proven efficacy in both weight reduction and cardiovascular outcome improvement marks a paradigm shift in treatment. These findings support early and sustained use of pharmacotherapy in high-risk individuals, highlighting a need for integrated, personalized care strategies in obesity management.
- Open Access
- 17 September 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (32) , 105421
Pressure-Volume Loop Optimization of Cardiac Resynchronization Therapy in a Left Ventricular Assist Device Patient
- 17 September 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (32) , 105421
Open AccessPressure-Volume Loop Optimization of Cardiac Resynchronization Therapy in a Left Ventricular Assist Device Patient
- Open Access
Non-Invasive Telemonitoring in Heart Failure: A Systematic Review
Background and Objectives: Heart failure (HF) represents a major public health challenge worldwide, with rising prevalence, high morbidity and mortality rates, and substantial healthcare costs. Non-invasive telemonitoring has emerged as a promising adjunct in HF management, yet its clinical effectiveness remains unclear. Materials and Methods: In this systematic review, we summarize randomized controlled trials (RCTs) between 2004 and 2024 examining the efficacy of non-invasive telemonitoring on mortality, readmission, and quality of life (QoL) in HF. In addition, we characterize the heterogeneity of features of different telemonitoring interventions. Results: In total, 32 RCTs were included, comprising 13,294 participants. While some individual studies reported benefits, non-invasive telemonitoring demonstrated mixed effects on mortality, readmission rates, and QoL. The most common modality for interfacing with patients was by mobile application (53%), followed by web portals (22%), and stand-alone devices (19%). Periodic feedback (63%) was more common than continuous feedback (31%) or on-demand feedback (6%). Clinician reviews of patient telemonitoring data was event-triggered (44%) more commonly than based on a prespecified timeline (38%). In most designs (90%), patients played a passive role in telemonitoring. Conclusions: Non-invasive telemonitoring interventions for HF exhibited considerable variation in duration and system design and had a low rate of patient engagement. Future work should focus on identifying telemonitoring-responsive subgroups and refining telemonitoring strategies to complement traditional HF care.
Open AccessNon-Invasive Telemonitoring in Heart Failure: A Systematic Review
Background and Objectives: Heart failure (HF) represents a major public health challenge worldwide, with rising prevalence, high morbidity and mortality rates, and substantial healthcare costs. Non-invasive telemonitoring has emerged as a promising adjunct in HF management, yet its clinical effectiveness remains unclear. Materials and Methods: In this systematic review, we summarize randomized controlled trials (RCTs) between 2004 and 2024 examining the efficacy of non-invasive telemonitoring on mortality, readmission, and quality of life (QoL) in HF. In addition, we characterize the heterogeneity of features of different telemonitoring interventions. Results: In total, 32 RCTs were included, comprising 13,294 participants. While some individual studies reported benefits, non-invasive telemonitoring demonstrated mixed effects on mortality, readmission rates, and QoL. The most common modality for interfacing with patients was by mobile application (53%), followed by web portals (22%), and stand-alone devices (19%). Periodic feedback (63%) was more common than continuous feedback (31%) or on-demand feedback (6%). Clinician reviews of patient telemonitoring data was event-triggered (44%) more commonly than based on a prespecified timeline (38%). In most designs (90%), patients played a passive role in telemonitoring. Conclusions: Non-invasive telemonitoring interventions for HF exhibited considerable variation in duration and system design and had a low rate of patient engagement. Future work should focus on identifying telemonitoring-responsive subgroups and refining telemonitoring strategies to complement traditional HF care.
- 11 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 40 (4) , 185-192
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Purpose of review: The increasing prevalence of hypertension, alongside the growing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for conditions beyond type 2 diabetes, underscores the need for understanding if there is a role for these medications in blood pressure management. This review addresses the timely opportunity to assess how GLP-1 RAs could influence blood pressure control, potentially broadening therapeutic strategies for cardiovascular risk management. Recent findings: Emerging literature indicates that GLP-1 RAs influence blood pressure through various mechanisms, such as sympathetic nervous modulation, vasodilation, and diuretic effects. Clinical trials demonstrate modest yet statistically significant reductions in systolic blood pressure (SBP), with less consistent effects on diastolic blood pressure (DBP). The advent of dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists presents enhanced possibilities for managing hypertension. Summary: The implications of these findings suggest that GLP-1 RAs have potential as adjunctive therapies for hypertension, especially in patients already receiving these agents for other cardiometabolic conditions. The blood pressure-lowering effects, often independent of weight loss or glucose control, warrant further investigation to determine their precise role within hypertension treatment algorithms and encourage integration into clinical practice.
- 11 April 2025
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 40 (4) , 185-192
Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Purpose of review: The increasing prevalence of hypertension, alongside the growing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for conditions beyond type 2 diabetes, underscores the need for understanding if there is a role for these medications in blood pressure management. This review addresses the timely opportunity to assess how GLP-1 RAs could influence blood pressure control, potentially broadening therapeutic strategies for cardiovascular risk management. Recent findings: Emerging literature indicates that GLP-1 RAs influence blood pressure through various mechanisms, such as sympathetic nervous modulation, vasodilation, and diuretic effects. Clinical trials demonstrate modest yet statistically significant reductions in systolic blood pressure (SBP), with less consistent effects on diastolic blood pressure (DBP). The advent of dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists presents enhanced possibilities for managing hypertension. Summary: The implications of these findings suggest that GLP-1 RAs have potential as adjunctive therapies for hypertension, especially in patients already receiving these agents for other cardiometabolic conditions. The blood pressure-lowering effects, often independent of weight loss or glucose control, warrant further investigation to determine their precise role within hypertension treatment algorithms and encourage integration into clinical practice.
- Open Access
HeartMate 3 upgrade and aortic root replacement for severe aortic insufficiency and ventricular fibrillation
- Open Access
- 18 September 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (18) , 102527
Eosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient
- 18 September 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (18) , 102527
Open AccessEosinophilic Endomyocarditis After COVID-19 Infection in a Heart Transplant Recipient
- 31 July 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (9) , 1509-1527
Obesity and Weight Loss Strategies for Patients With Heart Failure
- 31 July 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (9) , 1509-1527
Obesity and Weight Loss Strategies for Patients With Heart Failure
- 19 June 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (10) , 1661-1676
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
- 19 June 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (10) , 1661-1676
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
- 17 November 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 397, 131591
Anticoagulation in patients with atrial fibrillation and heart failure: More than meets the eye?
- 17 November 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 397, 131591
Anticoagulation in patients with atrial fibrillation and heart failure: More than meets the eye?